Fidrisertib
As of the edition of 20 October 2026, Fidrisertib is a small molecule: stopped in 2026; acts on ACVR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 2, 1 stopped early
- Disease areas
- Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACVR1 | Activin receptor type-1 | Q04771 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 2 |